Qvanteq AG develops novel biofunctional surfaces to address and overcome the clinical adverse effects of today’s medical devices and vascular stents. Qvanteq’s Qstent technology stands for reduced thrombus formation and fast healing. Qvanteq AG was founded in early 2009 and is held by private investors. Qvanteq is ISO 13485 certified. Qvanteq is a spin-off company from the Swiss Federal Institute of Technology (ETH) Zurich. The company was awarded with the CTI start-up label in 2012.
View Top Employees from Qvanteq AG| Website | http://qvanteq.com |
| Revenue | $6 million |
| Employees | 4 (0 on RocketReach) |
| Founded | 2009 |
| Address | 1 Technoparkstrasse, Zürich, Zurich 8005, CH |
| Phone | +41 44 500 98 90 |
| Technologies |
JavaScript,
HTML,
PHP
+12 more
(view full list)
|
| Industry | Medical Equipment Manufacturing, Manufacturing General, Biotechnology, Manufacturing, Science and Engineering, Developer Platform, Software, Medical, Health Care |
| SIC | SIC Code 38 Companies, SIC Code 384 Companies |
| NAICS | NAICS Code 339 Companies, NAICS Code 33 Companies |
Looking for a particular Qvanteq AG employee's phone or email?
Qvanteq AG Questions
The Qvanteq AG annual revenue was $6 million in 2024.
Qvanteq AG is based in Zürich, Zurich.
The NAICS codes for Qvanteq AG are [339, 33].
The SIC codes for Qvanteq AG are [38, 384].
Related Companies
